Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
32.15
+0.04 (0.12%)
At close: Sep 2, 2026, 4:00 PM EDT
31.51
-0.64 (-1.99%)
After-hours: Sep 2, 2026, 7:54 PM EDT
Quince Therapeutics Employees
Quince Therapeutics had 38 employees as of December 31, 2025. The number of employees increased by 2 or 5.56% compared to the previous year.
Employees
38
Change (1Y)
2
Growth (1Y)
5.56%
Revenue / Employee
n/a
Profits / Employee
-$2,433,579
Market Cap
32.70M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 38 | 2 | 5.56% | 38 | 0 |
| Dec 31, 2024 | 36 | 4 | 12.50% | 36 | 0 |
| Dec 31, 2023 | 32 | 11 | 52.38% | 32 | 0 |
| Dec 31, 2022 | 21 | -34 | -61.82% | 21 | 0 |
| Dec 31, 2021 | 55 | 17 | 44.74% | 55 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| NextCure | 40 |
| Kyntra Bio | 34 |
| Actinium Pharmaceuticals | 27 |
| BriaCell Therapeutics | 16 |
| Context Therapeutics | 15 |
| Barinthus Biotherapeutics | 14 |
| TransCode Therapeutics | 12 |
QNCX News
- 8 days ago - Quince Therapeutics Proxy statement: Proxy filing - Filings
- 13 days ago - Craig-Hallum bullish on Quince Therapeutics, initiates with a Buy - TheFly
- 13 days ago - Quince Therapeutics initiated with a Buy at Craig-Hallum - TheFly
- 17 days ago - Quince Therapeutics participates in a conference call with Cantor Fitzgerald - TheFly
- 17 days ago - Quince Therapeutics reports Q2 EPS ($12.31), consensus ($12.39) - TheFly
- 19 days ago - Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update - GlobeNewsWire
- 19 days ago - Quince Therapeutics Earnings release: Q2 2026 - Filings
- 19 days ago - Quince Therapeutics Quarterly report: Q2 2026 - Filings